Yahoo Finance • 5 months ago

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

Phathom Pharmaceuticals Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027 Up to an additional $100 million in non-dilutive capital available subject t... Full story

Mentioned:

• HTGC

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now comme... Full story

Yahoo Finance • 6 months ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional informatio... Full story

Yahoo Finance • 6 months ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) (“Phathom”) on behalf of the company’s investors. Since August 2023, shares of Phathom’s com... Full story

Yahoo Finance • 6 months ago

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major innovation in the U.S. Erosive GERD market in ov... Full story

Yahoo Finance • 7 months ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 years VOQUEZNA® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial evaluating VOQUEZNA in compa... Full story

Yahoo Finance • 7 months ago

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biop... Full story

Yahoo Finance • 7 months ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today tha... Full story

Yahoo Finance • 8 months ago

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studies Ne... Full story

Yahoo Finance • 9 months ago

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf life Submission of six-month stability data satisfies Ph... Full story

Yahoo Finance • a year ago

Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm

NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART), Chinook Therapeut... Full story

Mentioned:

• IART

Yahoo Finance • a year ago

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phatho... Full story

Yahoo Finance • a year ago

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the... Full story

Yahoo Finance • a year ago

Phathom Pharmaceuticals Reports First Quarter 2023 Results

FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported finan... Full story

Yahoo Finance • a year ago

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristics Meta-analysis shows potassium-competitor acid blocke... Full story

Yahoo Finance • a year ago

Phathom Pharmaceuticals, Inc: Company Investigated by the Portnoy Law Firm

LOS ANGELES, April 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action o... Full story

Yahoo Finance • a year ago

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) re... Full story

Yahoo Finance • a year ago

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarter Combined commercial launch of vonoprazan for erosive esoph... Full story

Yahoo Finance • a year ago

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) res... Full story

Yahoo Finance • a year ago

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resu... Full story